Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy C Thompson

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Molecular Cancer Research : MCR|September 10, 2009
Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progressionMasami Watanabe, Guang Yang, Guangwen Cao, et al.
BJU International|July 16, 2017
Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancerSpyridon P Basourakos, John W Davis, Brian F Chapin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated AktGustavo Ayala, Jun Yan, Rile Li, et al.
European Urology|December 6, 2020
Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional TherapiesWeranja Ranasinghe, Daniel D Shapiro, Hyunsoo Hwang, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2004
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patientsTakefumi Satoh, Bin S Teh, Terry L Timme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomyGuru Sonpavde, Timothy C Thompson, Rajul K Jain, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
The American Journal of Pathology|March 26, 2003
Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasisGuangwen Cao, Guang Yang, Terry L Timme, et al.
Technology in Cancer Research & Treatment|January 19, 2006
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancerMichael T Tetzlaff, Bin S Teh, Terry L Timme, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Molecular Cancer Research : MCR|September 10, 2009
Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progressionMasami Watanabe, Guang Yang, Guangwen Cao, et al.
BJU International|July 16, 2017
Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancerSpyridon P Basourakos, John W Davis, Brian F Chapin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated AktGustavo Ayala, Jun Yan, Rile Li, et al.
European Urology|December 6, 2020
Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional TherapiesWeranja Ranasinghe, Daniel D Shapiro, Hyunsoo Hwang, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2004
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patientsTakefumi Satoh, Bin S Teh, Terry L Timme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomyGuru Sonpavde, Timothy C Thompson, Rajul K Jain, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
The American Journal of Pathology|March 26, 2003
Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasisGuangwen Cao, Guang Yang, Terry L Timme, et al.
Technology in Cancer Research & Treatment|January 19, 2006
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancerMichael T Tetzlaff, Bin S Teh, Terry L Timme, et al.
Pageof 12